Analyst Research Roundup: AMERI Holdings, Inc. (AMRH), Titan Pharmaceuticals, Inc. (TTNP)

AMERI Holdings, Inc. (NASDAQ:AMRH) tinted gains of +1.82% (0 points) to US$0.23. The volume of 0.41 Million shares climbed down over an trading activity of 1.48 Million shares. EPS ratio determined by looking at last 12 month figures is -0.12. Over the same time span, the stock marked US$3 as its best level and the lowest price reached was US$0.15. The corporation has a market cap of US$9.69 Million.

AMERI Holdings, Inc. (NASDAQ:AMRH)’s earnings per share has been growing at a 0 percent rate over the past 5 year when average revenue increase was noted as 0 percent. The return on equity ratio or ROE stands at -5.3 percent while most common profitability ratio return on investment (ROI) was -36 percent. The company’s institutional ownership is monitored at 4.7 percent. The company’s net profit margin has achieved the current level of -2.6 percent and possesses 20.6 percent gross margin.

Daily Analyst Recommendations

A number of key analysts, polled by FactSet, shared their views about the current stock momentum. The forecast of 1 surveyed investment analysts covering the stock advises investors to Buy stake in the company. At present, 0 analysts call it Sell, while 0 think it is Hold. Recently, analysts have updated the overall rating to 1. 0 analysts recommended Overweight these shares while 0 recommended Underweight, according to FactSet data.

Titan Pharmaceuticals, Inc. (NASDAQ:TTNP) is worth US$93.57 Million and has recently fallen -7.69% to US$1.2. The latest exchange of 0.6 Million shares is below its average trading activity of 795.65 Million shares. The day began at US$1.2 but the price moved to US$1.2 at one point during the trading and finally capitulating to a session high of US$1.2. The stock tapped a 52-week high of US$8.4 while the mean 12-month price target for the shares is US$0.

Currently, the stock carries a price to earnings ratio of 0, a price to book ratio of 8.63, and a price to sales ratio of 17.2. For the past 5 years, the company’s revenue has grown 0%, while the company’s earnings per share has grown 0%. With an institutional ownership near 5.98%, it carries an earnings per share ratio of -0.45.

Inside Look At Analysts Reviews

Latest analyst recommendations could offer little help to investors. The stock is a Buy among 0 brokerage firms polled by Factset Research. At present, 0 analysts recommended Holding these shares while 0 recommended sell, according to FactSet data. 0 analysts call it Underweight, while 1 think it is Overweight. Recently, investment analysts covering the stock have updated the mean rating to 2.